Swedish Diversified Financial Stock News

Devyser Diagnostics (OM:DVYSR) remains unprofitable, with losses deepening at an annual rate of 16.9% over the past five years. However, revenue is forecast to surge by 31.1% per year, outpacing the Swedish market’s 3.7% per year projected growth, and earnings are expected to rise sharply by 119.62% per year with profitability anticipated within the next three years. With the share price trading at SEK 115, well below the estimated fair value of SEK 583.07, investors are likely to focus on...

Oncopeptides (OM:ONCO) remains unprofitable, but has aggressively narrowed its losses by 43.3% per year over the past five years. With earnings expected to surge by 95.25% each year and profitability projected within the next three years, investors have plenty to weigh against near-term risks as the company targets annual revenue growth of 71.2%, far outpacing the wider Swedish market. See our full analysis for Oncopeptides. The next step is to see how these figures compare with the broader...

Orrön Energy (OM:ORRON) remains in the red, with losses compounding at an average annual rate of 57.4% over the last five years and profit margins still under pressure. While profitability is not expected in the next three years, revenue is forecast to surge at 19.15% per year, outpacing the Swedish market’s 3.7% average. Investors are left weighing Orrön’s premium valuation and strong revenue growth outlook in comparison to a track record of persistent losses and little evidence that a...

Cloetta (OM:CLA B) delivered standout earnings results this year, with EPS jumping 56.7% compared to its historical average of 14.3% annual growth over the past five years. Net profit margin rose to 8.3%, outpacing last year's 5.4%. However, revenue growth projections of 1.6% per year lag the broader Swedish market's 3.7%. Investors will note that while the company's valuation looks appealing versus industry peers, forecasts now expect earnings to decline by 1.8% per year over the next three...

Storskogen Group (OM:STOR B) just turned profitable, with its net profit margin moving into positive territory for the past year. The company’s earnings include a one-off gain of SEK910.0 million in the latest 12 months ending September 30, 2025, which clouds the picture of underlying profit quality. Over the past five years, earnings have declined by 10.2% per year, and with revenue expected to grow at just 2.9% per year, which is slower than both the broader Swedish market and sector peers,...

Haypp Group (OM:HAYPP) reported a net profit margin of 1.6%, more than doubling last year’s 0.7%. Earnings over the past year surged 118.4%, well ahead of the company’s five-year average annual growth of 73.9%. Revenue is forecast to climb 20.7% per year, far outpacing the Swedish market average of 3.7%, while earnings are projected to rise 60.1% annually compared to the market average of 12.8%. With Haypp becoming profitable over the past five years and profit growth gaining speed in both...

Medicover (OM:MCOV B) reported a jump in its net profit margin to 2.9%, up from 1% last year. Earnings soared 241.6% over the past twelve months, reversing a five-year trend in which profits shrank by an average of 16.9% each year. Looking ahead, revenue is forecast to grow at 11.3% annually and earnings at 27.1% per year, both of which are ahead of the Swedish market averages. These numbers set up a compelling backdrop for investors, who will now weigh Medicover’s operational momentum and...

Kambi Group (OM:KAMBI) reported a 23.7% annual decline in earnings over the past five years, with its latest net profit margin narrowing to 4.3% from 9% a year ago. Despite the recent margin compression, forecasts point to a striking projected earnings growth of 57.35% per year. This rate would outpace both the market’s 12.8% expected profit growth and a strong 6.8% annual revenue growth outlook. These figures set the stage for a company that is wrestling with profitability pressures, yet...

Cheffelo (OM:CHEF) posted a net profit margin of 4.5%, up from 2.4% last year, with annualized earnings growth of 45.2% over the past five years and a standout 115.8% jump in the most recent year. Looking ahead, analysts forecast annual profit growth of 22.2% and revenue growth of 7.6%, both ahead of Swedish market averages. Earnings are modeled to expand by more than 20% annually through the next three years. Investors are likely to weigh these rapid growth trends and high-quality reported...

EQL Pharma (OM:EQL) is projecting standout rates, with earnings forecast to climb 59.57% per year and revenue expected to grow 30.4% annually, far outpacing the Swedish market’s 3.7% revenue growth outlook. Over the past five years, the company saw earnings rise by 19.1% each year and currently holds a net profit margin of 7.4%, down from last year’s 9.9%. With a Price-to-Earnings ratio of 54.3x, EQL trades above the broader European healthcare sector but remains slightly below its immediate...

KABE Group AB (publ.) (STO:KABE B) has had a rough three months with its share price down 15%. However, the company's...

Hacksaw (OM:HACK) posted standout forecasts this season, with earnings expected to grow 37.6% per year and revenue projected to rise 26.4% annually. Both are comfortably ahead of the Swedish market’s 12.8% and 3.7% rates, respectively. The company’s net profit margins remain robust at 64.1%, and shares are trading at a Price-To-Earnings ratio of 15.6x, which looks attractive versus industry peers. Investors will likely welcome the absence of flagged risks as well as the current share price of...

The European stock market has experienced mixed performance recently, with the pan-European STOXX Europe 600 Index ending slightly lower amid tempered expectations for further interest rate cuts by the European Central Bank. Despite this, certain stocks in Europe may be trading below their intrinsic value, offering potential opportunities for investors who focus on fundamental analysis and long-term growth prospects in a cautious economic environment.

SaltX Technology Holding (OM:SALT B) remains unprofitable, with net profit margins showing no improvement over the last year and losses deepening by 10.5% annually over the past five years. The Price-to-Sales Ratio stands at 18.7x, which is a substantial premium to both the Swedish machinery industry average of 1.8x and the peer group’s 2.8x. With shares trading at such a high valuation despite mounting losses and no visible improvement in profitability, the current results underline the...

AB Volvo (OM:VOLV B) shares have attracted attention recently, following a period of mixed returns over the past month. Investors are taking a closer look at how the company’s fundamentals stand up, especially after a recent dip in the stock price. See our latest analysis for AB Volvo. Over the past year, AB Volvo’s shareholders have seen a total return of just over 1%, with long-term investors rewarded by a more impressive 69% total return over three years and more than doubling their money...

In recent weeks, the European market has experienced mixed performances across major stock indexes, with the pan-European STOXX Europe 600 Index declining slightly as expectations for further interest rate cuts from the European Central Bank diminished. Amid this backdrop of cautious monetary policy and steady inflation rates near target levels, investors are increasingly on the lookout for stocks that may be trading below their fair value, offering potential opportunities in a market...

As the European markets navigate a period of mixed performances, with the pan-European STOXX Europe 600 Index recently pulling back slightly after reaching new highs, investor attention is increasingly focused on companies that demonstrate resilience and potential for growth. In this context, growth companies with high insider ownership can be particularly appealing as they often signal strong internal confidence and alignment of interests between management and shareholders.

Strong earnings weren't enough to please Botnia Gold AB (publ)'s ( STO:BOTX ) shareholders over the last week. Our...

Key Insights Bergman & Beving's estimated fair value is kr355 based on 2 Stage Free Cash Flow to Equity With kr320...

Most readers would already be aware that ByggPartner Gruppen's (STO:BYGGP) stock increased significantly by 67% over...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Last week, you might have seen that AcadeMedia AB (publ) ( STO:ACAD ) released its quarterly result to the market. The...

When companies post strong earnings, the stock generally performs well, just like Scandic Hotels Group AB (publ)'s...

MedCap AB (publ)'s ( STO:MCAP ) stock showed strength, with investors undeterred by its weak earnings report...